# Pembrolizumab in Neoplasms or Lymphomas

> **NCT03316573** · PHASE2 · SUSPENDED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 18 (actual)

## Conditions studied

- Lymphoma
- Histiocytic Sarcoma
- Follicular Dendritic Cell Sarcoma
- Interdigitating Dendritic Cell Sarcoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03316573
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2017-12-07
- **Primary completion:** 2022-08-18
- **Final completion:** 2026-03-01
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03316573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03316573, "Pembrolizumab in Neoplasms or Lymphomas". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03316573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*